Rizatriptan: Nursing Drug Guide, Serotonin Syndrome & Hold Rules
Rizatriptan stops a migraine attack by activating cranial 5-HT1B/1D receptors—but the bedside danger is stacking serotonergic drugs (SSRIs, SNRIs, MAO inhibitors) and missing cardiovascular contraindications. Screen every MAR line for another triptan or ergot in the last 24 hours, confirm blood pressure control, and treat new agitation, hyperreflexia, or crushing chest pain as emergencies—not “just migraine.”
Life-threatening serotonin syndrome can develop within minutes to hours when rizatriptan is combined with SSRIs, SNRIs, TCAs, or MAO inhibitors—discontinue rizatriptan immediately if agitation, autonomic instability, hyperreflexia, or altered mental status occur. Triptans can also cause myocardial ischemia, stroke, and severe chest or neck vasospasm; rizatriptan is contraindicated with ischemic heart disease, stroke/TIA history, uncontrolled hypertension, or another triptan/ergot within 24 hours.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: reconcile serotonergic drugs and 24-hour triptan/ergot use, confirm no cardiovascular contraindications, and cap adults at 30 mg/24 h (15 mg/24 h on propranolol). Teach patients that neck or chest pressure needs urgent assessment if severe—and that “another triptan” at home still counts toward the 24-hour limit.
Most common brand names
Rizatriptan is the generic name; most nurses see it under brand labels or as the benzoate salt on prescriptions.
Common brands include Maxalt (film-coated tablets) and Maxalt-MLT (orally disintegrating tablets). Prescribing information also lists rizatriptan benzoate tablets and ODTs from multiple manufacturers. Rizatriptan is not typically supplied as a fixed-dose combination product in the reviewed labeling. Institutional formularies and product formulations may vary.
Why we give it — Indications
Rizatriptan is an acute migraine therapy—not prevention. Nurses should confirm the patient has an established migraine diagnosis and is not treating an undifferentiated severe headache that could represent another neurologic emergency.
| Use | Detail |
|---|---|
| Acute migraine with or without aura (adults) | Treat moderate to severe migraine attacks after diagnosis is established. If there is no response to the first treated attack, reconsider the migraine diagnosis before repeat prescribing per labeling. |
| Acute migraine (pediatric patients 6–17 years) | Weight-based dosing: 5 mg if <40 kg (88 lb), 10 mg if ≥40 kg. Safety of more than one dose within 24 hours in pediatrics has not been established. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Rizatriptan is a selective 5-HT1B/1D receptor agonist (triptan). It binds receptors on intracranial blood vessels and trigeminal sensory nerves, producing cranial vasoconstriction and inhibiting pro-inflammatory neuropeptide release—relieving migraine headache and associated symptoms when given early in an attack.
Dosing overview
Dosing is weight- and interaction-dependent. Always verify propranolol co-therapy and count every triptan dose in the rolling 24-hour window before administration.
Missed dose: Not applicable to scheduled therapy—rizatriptan is taken PRN at migraine onset. Do not exceed per-24-hour maximum if the patient already took doses at home; include home use in the 24-hour total.
Before you give it — Safety check
Pretreatment checks
- Confirm migraine diagnosis and that headache is not a new, severe, or atypical neurologic presentation requiring alternate workup
- Review cardiovascular history, blood pressure, and risk factors (age, diabetes, smoking, obesity, family history of CAD); perform medication reconciliation for triptans, ergots, SSRIs, SNRIs, TCAs, and MAO inhibitors
- Verify no triptan or ergotamine dose within 24 hours and that this dose will not exceed the 24-hour rizatriptan maximum (30 mg adults; 15 mg if on propranolol)
Contraindications
- Ischemic coronary artery disease, coronary vasospasm (including Prinzmetal angina), history of stroke or TIA, peripheral vascular disease, or ischemic bowel disease
- Uncontrolled hypertension, hemiplegic or basilar migraine, or use of another 5-HT1 agonist or ergotamine within 24 hours
- MAO-A inhibitor within 2 weeks or known hypersensitivity to rizatriptan (angioedema/anaphylaxis reported)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| SSRIs / SNRIs (e.g., sertraline, fluoxetine) | Increased serotonin syndrome risk—mental status changes, autonomic instability, hyperreflexia, GI symptoms | Screen before every dose; teach red flags; stop rizatriptan and escalate urgently if syndrome suspected; involve prescriber/pharmacist for ongoing therapy decisions |
| Other triptans / ergotamine (24-hour window) | Contraindicated combination—prolonged vasospasm and severe vasoconstrictive effects | Hold dose; document last triptan/ergot time from patient and MAR; clarify alternate acute therapy with prescriber |
| Propranolol | Propranolol increases rizatriptan AUC ~70%; higher exposure increases adverse reactions | Adults: only 5 mg rizatriptan, max 3 doses/24 h; pediatrics ≥40 kg on propranolol: single 5 mg only; do not give if <40 kg on propranolol |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral—swallow conventional tablets whole with water, or place ODT on tongue to dissolve (liquid not required). May give without regard to food.
- Give at the start of the migraine attack for best response; not for prevention or cluster headache per labeling
- ODT: do not remove from blister until dosing; peel open with dry hands; allow to dissolve on tongue and swallow with saliva per medication administration standards
- Document exact time of each dose to enforce the 2-hour minimum interval and 24-hour maximum
Cerebrovascular events have occurred when 5-HT1 agonists were given for non-migraine headaches. Exclude other serious neurologic conditions before first use in undiagnosed patients, and reassess diagnosis if the first treated attack does not respond.
Expected therapeutic response
- Reduction in migraine headache intensity—often within 1–2 hours (headache response defined as moderate/severe pain reduced to mild or none in trials)
- Improvement in associated symptoms such as nausea, photophobia, or phonophobia when responsive to therapy
- If no relief after first dose, labeling advises reconsidering migraine diagnosis before treating subsequent attacks—do not automatically repeat without prescriber review
Red flags — Stop and act
Triptan adverse effects overlap migraine and cardiac symptoms. Any vasospastic or serotonergic red flag requires stopping the drug and escalating—not reassurances alone.
- Agitation, hallucinations, confusion, hyperreflexia, clonus, diaphoresis, or labile blood pressure suggesting serotonin syndrome—stop rizatriptan and serotonergic partners; urgent escalation
- Severe, persistent, or atypical chest pain, pressure, or tightness; syncope; or new neurologic deficits—possible myocardial ischemia or cerebrovascular event
- Sudden severe abdominal pain with bloody diarrhea—possible gastrointestinal ischemia per vasospasm warnings
- Marked dizziness, somnolence, palpitations, or arrhythmia symptoms after dose—discontinue and obtain ECG per protocol
- Facial swelling, urticaria, or respiratory distress after dose—possible anaphylaxis; stop permanently
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Asthenia / fatigue, somnolence, dizziness | Common in adults (≥5% and greater than placebo; dose-related per labeling) | Assess fall risk and ability to drive; hold further doses if excessive sedation; document and notify prescriber if impairment persists |
| Pain / pressure sensation (chest, neck, throat, jaw) | Common; usually non-cardiac but cardiac origin must be excluded | Obtain vital signs and focused assessment; escalate for cardiac evaluation if atypical, severe, or with other ischemic cues |
| Nausea and digestive symptoms | Common (≥5% in some dose groups) | Supportive care; distinguish from serotonin syndrome when serotonergic drugs are co-prescribed |
| Paresthesia / atypical sensations | Reported ≥2% in adult trials | Document timing relative to dose; notify prescriber if persistent or concerning |
| Serotonin syndrome | Serious; reported with triptans plus SSRIs/SNRIs/TCAs/MAO inhibitors | Stop rizatriptan, discontinue interacting serotonergic drugs per prescriber, escalate urgently for autonomic or mental-status changes |
| Myocardial ischemia, arrhythmias, cerebrovascular events | Serious; rare but potentially fatal per warnings | Discontinue dosing, obtain ECG and emergency evaluation per protocol |
| Hypersensitivity (angioedema, anaphylaxis) | Post-marketing reports | Stop drug permanently; treat per anaphylaxis protocol; never rechallenge |
On a small screen, swipe or scroll sideways to see the full table.
Frequency data reflect rizatriptan benzoate prescribing information from controlled adult trials unless noted.
Overdose, toxicity, and antidote
No overdoses of rizatriptan benzoate were reported during adult clinical trials. In overdose studies and reports, dizziness, somnolence, syncope, bradycardia (including third-degree AV block), vomiting, and incontinence have occurred at high cumulative doses per prescribing information.
Expected toxicity
- Based on pharmacology, hypertension or myocardial ischemia could occur after overdosage
- High cumulative exposure may cause pronounced dizziness, somnolence, and cardiovascular rhythm disturbances
Antidote
No specific antidote is listed in the reviewed prescribing information. Management is supportive with clinical and electrocardiographic monitoring for at least 12 hours, even if symptoms are absent. Gastrointestinal decontamination (gastric lavage followed by activated charcoal) may be considered in suspected overdose. Effects of hemo- or peritoneal dialysis on serum rizatriptan concentrations are unknown.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Rizatriptan vs sumatriptan and other triptans—verify the exact 5-HT1 agonist on the MAR; another triptan within 24 hours is contraindicated
- Maxalt vs Maxalt-MLT—film-coated tablet vs orally disintegrating tablet; administration technique differs (ODT dissolves on tongue without liquid)
- 5 mg vs 10 mg—higher dose may improve response but increases adverse reactions; patients on propranolol require dose reduction to 5 mg only
- 24-hour triptan/ergot stacking—most common outpatient error; reconcile home PRN migraine meds at every encounter
- SSRI/SNRI co-prescription—serotonin syndrome risk is not prevented by using a “different” triptan; verify serotonergic drug list before first inpatient dose
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| When to give | Acute migraine therapy—administer at headache onset after safety screen; not for migraine prevention per labeling |
| Repeat dosing | Adults may repeat after ≥2 hours if headache returns; do not exceed 30 mg in 24 hours (15 mg max if on propranolol) |
| ODT handling | Leave blister in carton until dosing; peel with dry hands; place on tongue to dissolve—liquid not required |
| Food | May be given without regard to food per labeling; food delays peak by about 1 hour |
| Phenylketonuria | ODT contains phenylalanine (aspartame): 0.84 mg per 5 mg tablet and 1.68 mg per 10 mg tablet per labeling |
| Commonly missed | Home triptan taken before arrival; SSRI started after discharge from prior visit; ergotamine-containing products within 24 hours |
| Ask pharmacy when | Propranolol interaction, MAO inhibitor history, unclear 24-hour triptan total, or moderate hepatic impairment dose questions |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Cardiovascular risk factors without established CAD | Triptan-naïve patients with multiple risk factors should have cardiovascular evaluation before first dose; consider first dose in medically supervised setting with ECG afterward per labeling. |
| Older adults (≥65 years) | Start at low end of dosing range; greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease. Cardiovascular evaluation advised when risk factors present. |
| Moderate hepatic impairment / hemodialysis | Higher plasma exposure possible; dose cautiously and involve pharmacy. Specific rizatriptan dose adjustments not fully specified for hemodialysis in reviewed labeling. |
| Pregnancy | No adequate and well-controlled studies in pregnant women. Animal studies showed developmental toxicity at high exposures. A pregnancy registry did not identify a clear pattern of malformations, but data were limited. Use during pregnancy only if potential benefit justifies potential risk per labeling. |
| Lactation | No data on rizatriptan in human milk or effects on breastfed infants. Rizatriptan was excreted in rat milk at levels ~6× maternal plasma. Weigh developmental benefits of breastfeeding against clinical need and potential infant exposure; consult LactMed and prescriber. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure before and after early doses, especially with cardiovascular risk factors or if hypertension history
- Mental status, reflexes, temperature, and heart rate when SSRIs/SNRIs/TCAs are co-prescribed—screen for serotonin syndrome for hours after dose
- Pain assessment and migraine response (timing, severity, associated symptoms); track 24-hour dose total and interval since last triptan
Document
- Dose, formulation (tablet vs ODT), time, indication, and running 24-hour rizatriptan total including home doses reported
- Cardiovascular and serotonergic medication review completed; blood pressure; patient education on chest symptoms and serotonin syndrome
- Response to dose, adverse effects, and prescriber/pharmacist contact when dose held for interaction or contraindication
Patient teaching
- Take at the first sign of migraine; do not use to prevent attacks or for headaches you have not discussed with your prescriber
- Do not take another triptan or ergot medicine within 24 hours of rizatriptan; tell your team about every migraine medicine you use, including OTC and samples
- Seek urgent care for sudden severe chest, neck, or jaw pain, shortness of breath, weakness on one side, or the worst headache of your life
- Tell your care team about antidepressants, anxiety medicines, or MAO inhibitors—report agitation, fast heartbeat, fever, muscle twitching, or confusion after rizatriptan
- Do not drive or operate machinery if you feel dizzy or sleepy after a dose; rizatriptan may cause somnolence per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Uncontrolled hypertension, active chest pain, suspected acute coronary syndrome, or new neurologic deficits
- Another triptan or ergotamine within 24 hours, or this dose would exceed 30 mg/24 h (15 mg/24 h on propranolol)
- MAO inhibitor within 2 weeks, known rizatriptan allergy, or signs of serotonin syndrome
- Order exceeds 5 mg while patient takes propranolol (or pediatric <40 kg on propranolol—any rizatriptan held)
- Hemiplegic or basilar migraine, history of stroke/TIA, ischemic heart disease, or peripheral vascular disease—contraindicated; notify prescriber for alternate therapy
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Rizatriptan is often a home PRN medicine brought to the ward during a migraine flare—or ordered in the ED. The nursing workflow is interaction screening and vasospasm vigilance, not simply handing over a tablet.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right 24-hour triptan total including home use
- Serotonergic drug scan: SSRIs, SNRIs, TCAs, MAO inhibitors, other triptans, ergot derivatives
- Blood pressure and cardiovascular history; propranolol interaction check (5 mg cap)
- Confirm headache fits established migraine pattern—not a new thunderclap or focal neurologic presentation
2. High-alert and safety badge
Not a universal ISMP high-alert medication, but vasospasm and serotonin syndrome carry high-stakes riskAlthough rizatriptan is not on all institutional high-alert lists, labeling warns of serious cardiac, cerebrovascular, and serotonergic events. Use the same disciplined interaction and contraindication checks you would apply to high-risk vasoactive drugs.
3. Clinical workflow: hold and question rules
- If the patient took sumatriptan at home this morning, hold rizatriptan even if the migraine is severe—clarify timing and alternate therapy
- If the patient reports neck tightness after dose, assess vitals and cardiac symptoms before offering a repeat dose
- Escalate immediately for autonomic instability or hyperreflexia on an SSRI—do not administer another serotonergic PRN without prescriber review
4. Critical teach-back questions
- “What other headache medicines must you avoid for 24 hours after rizatriptan?” (Patient should name other triptans and ergotamine-containing drugs and agree to tell the team about all migraine medicines.)
- “What symptoms mean you need emergency care after rizatriptan?” (Patient should include severe chest/neck pain, one-sided weakness, confusion/agitation with fever or rapid heartbeat, or sudden worst headache.)
5. Care coordination
Pharmacist: Clarify propranolol dose limits, MAO inhibitor washout, 24-hour triptan totals, and serotonergic interaction plans when inpatient orders differ from home meds
Prescriber / neurology or cardiology: Notify for failed first response (reconsider diagnosis), recurrent disabling migraine, cardiovascular symptoms, or need for preventive therapy instead of repeated acute triptans
🧠 Quick mental checklist
- What serotonergic drugs and triptans/ergots are on the MAR and home list?
- What is the 24-hour rizatriptan total—including doses before arrival?
- Is blood pressure controlled and is there any CAD, stroke, or PVD history?
- Is the patient on propranolol (5 mg dose cap)?
- If chest tightness or agitation appears, is this vasospasm, cardiac ischemia, or serotonin syndrome?
Rizatriptan NCLEX practice questions
Practice NCLEX-style clinical judgment practice for rizatriptan using a tabbed case (MAR, labs, vitals/history, nursing notes), then work through priority action, select-all-that-apply cue and trend items, matrix urgency sorting, clinical judgment, and documentation cloze—recognise serotonergic and vasospasm cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, Vitals/History, and nursing note details for this case.
- Sertraline 50 mg PO daily — given 0800
- Rizatriptan 10 mg PO PRN migraine — ordered; not yet given this admission
- Propranolol 40 mg PO BID — given 0800
- Home med list: patient took sumatriptan 50 mg at 0700 before arrival (6 hours ago)
- 1130: patient rates migraine 8/10; requests rizatriptan
- No routine labs required before single acute dose
- Admission BMP: within reference range
- ECG (outpatient, 6 months ago): normal sinus rhythm per chart
- If serotonin syndrome suspected: no specific lab test—diagnosis is clinical
- BP 138/86 mmHg; HR 92/min; RR 16/min; SpO2 98% on room air; temp 37.1 °C
- 32-year-old with established migraine with aura; no CAD, stroke, or PVD documented
- Smoker (5 cigarettes/day); no diabetes
- Reports photophobia and nausea with current attack
- 1100: Headache with typical aura; neuro exam non-focal
- 1120: Medication reconciliation completed—home sumatriptan at 0700 noted
- 1130: Patient asking for rizatriptan; nurse reviewing interaction and 24-hour triptan rules before administration
Answer key & rationale
Frequently asked questions
Can rizatriptan be given with an SSRI or SNRI?
Prescribing information warns that serotonin syndrome may occur with triptans during co-administration with SSRIs, SNRIs, TCAs, and MAO inhibitors. Concurrent use is not an absolute contraindication in the label, but nurses must screen the medication list, teach patients about serotonin syndrome symptoms, and stop rizatriptan and escalate urgently if agitation, autonomic instability, hyperreflexia, or altered mental status develop.
How soon can a patient take another triptan or ergotamine after rizatriptan?
Rizatriptan is contraindicated if another 5-HT1 agonist (such as another triptan) or an ergotamine-containing medication was used within the previous 24 hours. For adults, a second rizatriptan dose may be given at least 2 hours after the first dose if the headache returns, but total rizatriptan must not exceed 30 mg in any 24-hour period (15 mg if the patient takes propranolol).
When should a nurse hold rizatriptan and contact the prescriber or pharmacist?
Hold for uncontrolled hypertension, history of ischemic heart disease, stroke or TIA, peripheral vascular disease, hemiplegic or basilar migraine, MAO inhibitor use within 2 weeks, another triptan or ergot within 24 hours, suspected serotonin syndrome, new severe chest pain, or hypersensitivity. Also hold and clarify if the 24-hour dose limit would be exceeded or if the patient is on propranolol and the order exceeds 5 mg per dose.
What should patients do if chest tightness occurs after rizatriptan?
Chest, throat, neck, or jaw tightness, pain, pressure, or heaviness commonly occur with triptans and are often non-cardiac. However, a cardiac origin must be excluded. Patients should seek urgent evaluation for severe, persistent, or atypical symptoms, especially with cardiovascular risk factors, and should not take another dose until assessed.
Is there an antidote for rizatriptan overdose?
No specific antidote is listed in prescribing information. Overdose management is supportive, with clinical and electrocardiographic monitoring for at least 12 hours. Hypertension or myocardial ischemia may occur. Contact local poison control or medical toxicology services per facility protocol.
References
-
U.S. National Library of Medicine. Rizatriptan benzoate orally disintegrating tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29e066-c018-22e7-e063-6294a90a035c
-
U.S. National Library of Medicine. Rizatriptan tablet, film coated — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f000d96c-42a0-4aac-96ca-8cef289979ce
-
Drugs and Lactation Database (LactMed). Rizatriptan. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM578/
-
National Institute for Health and Care Excellence. Headaches in over 12s: diagnosis and management (NG150).https://www.nice.org.uk/guidance/ng150
-
U.S. Food and Drug Administration. MedWatch — Report adverse events.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.